Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety […]
Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by […]
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish […]
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer […]
OrthoPediatrics Corp. Announces Preliminary Unaudited Financial Highlights for the Fourth Quarter & Full Year 2023
WARSAW, Ind., Jan. 08, 2024 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively […]
TSX News -
Enthusiast Gaming Announces Appointment of Interim Chief Executive Officer
LOS ANGELES, Jan. 08, 2024 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), the […]
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever […]
WiMi Developed PBO-Based Dynamic Optimization Algorithm That Can Be Applied to Blockchain and Bitcoin Trading Strategies
Beijing, Jan. 08, 2024 (GLOBE NEWSWIRE) — WiMi Hologram Cloud Inc. (NASDAQ: WIMI) (“WiMi” or the “Company”), a leading global […]
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea […]
Bionano Reports Preliminary Fourth Quarter and Full-Year 2023 Results
Preliminary Q4 2023 revenue expected to be between $10.4 and $10.7 million, which would represent an estimated increase of 27% […]
